For the first time, analyst group lowers 2022 sales forecast as pricing backlash takes a toll

Fierce Pharma ------- For a decade, each new projection for drug sales from analyst group Evaluate has been higher than the last as new blockbusters and price hikes have pushed up its forecasts. Not this year. For the first time since it has been publishing its World Preview reports, the life science commercial intelligence firm has lowered its forecast for industrywide drug sales, based largely on new attention to pricing. While some standout performances from drugs like cancer meds Keytruda and Opdivo will continue to push drug sales upward, Evaluate has reduced its 2022 projection by $60 billion, to $1.06 trillion. That is down from the $1.12 trillion in 2022 sales it had projected last year. To learn more click on the picture below to read the article.